Division of Pharmaceutics
College of Pharmacy, University of Iowa
115 S. Grand Avenue, S418 PHAR
Iowa City, IA 52242
Education and Training
2012 PhD (Clinical and Experimental Therapeutics), University of Kentucky
2007 - 2008 PGY-1 Pharmacy Practice Residency, University of Kentucky HealthCare
2007 PharmD, The University of Iowa
2003 BS (Biology), The University of Iowa
Certification and Licensure
2011 Graduate Certificate in Clinical and Translational Science, University of Kentucky
2008 Scholarship of Teaching and Learning Certificate, University of Kentucky
2007 - present Pharmacist licensure, Kentucky
Dr. Brogden's laboratory provides a translational and interdisciplinary setting in which clinical and benchtop research training intersect, allowing a fluid transition between benchtop, animal, and human research studies. Current collaborations include Dermatology, Dentistry, Family Medicine, and Internal Medicine. Several exciting projects are underway, in the following areas:
- Transdermal and topical delivery systems: exploring active means of transiently disrupting the skin barrier, primarily focusing on microneedle delivery systems
- Inflammatory skin diseases: investigating new means of locally treating skin lesions with novel drug delivery systems.
- Improving drug delivery and access to healthcare in unique patient populations including geriatric, pediatric, and LGBTQ (Lesbian, Gay, Bisexual, Transgender, Queer, and Questioning) patients.
Honors and Awards
2013-2014 New Investigator Award from the American Association of Colleges of Pharmacy
Brogden NK, Banks SL, Crofford LJ, and Stinchcomb AL. Diclofenac Enables Unprecedented Week-Long Microneedle-Enhanced Delivery of a Skin Impermeable Medication in Humans. Pharm Res. Jun 13, 2013. [Epub ahead of print] PubMed PMID: 23761054.
Ghosh P, Brogden NK, Stinchcomb AL. Effect of Formulation pH on Transport of Naltrexone Species and Pore Closure in Microneedle-Enhanced Transdermal Drug Delivery. Mol Pharm;10(6):2331-9, 2013.
Brogden NK, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Development of in vivo impedance spectroscopy techniques for measurement of micropore formation following microneedle insertion. J Pharm Sci. 102(6):1948-56, 2013.
Brogden NK, Milewski M, Ghosh P, Hardi L, Crofford LJ, Stinchcomb AL. Diclofenac delays micropore closure following microneedle treatment in human subjects. Journal of Controlled Release. Aug; 16(3):220-29, 2012. PMID: 22929967
Brogden NK, Mehalick L, Fischer CL, Wertz PW, Brogden KA. Review - The emerging role of peptides and lipids as antimicrobial epidermal barriers and modulators of local inflammation. Skin Pharmacology and Physiology. 25(4):167-81, 2012. PMID: 22538862
Brogden NK, Brogden KA. Review - Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? International Journal of Antimicrobial Agents. Sep;38(3):217-25, 2011. PMID: 21733662
Banks SL, Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharmaceutial Research. May;28(5):1211-9, 2011. PMID: 21301935
Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in transdermal delivery. Therapeutic Delivery. July;1(1):109 – 131, 2010.
Banks SL, Pinninti RR, Gill HS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs in vivo. Journal of Pharmaceutical Sciences. Jul;99(7):3072-80, 2010. PMID: 20166200
Milewski M, Brogden NK, Stinchcomb AL. Current aspects of formulation efforts and pore lifetime related to microneedle treatment of skin. Expert Opinion on Drug Delivery. May;7(5):617-29, 2010. PMID: 20205604
Florang VF, Rees JR, Brogden NK, Anderson DG, Hurley TD, and Doorn JA. Inhibition of mitochondrial aldehyde dehydrogenase-mediated oxidation of 3,4-dihydroxyphenylacetaldehyde. In Enzymology and Molecular Biology of Carbonyl Metabolism 13. (Weiner, E., Maser, E., Lindahl, R. and Plapp, B., Eds.) pp. 33-39, Purdue University Press, West Lafayette, Indiana, 2007.
Florang VF, Rees JR, Brogden NK, Anderson DG, Hurley TD, and Doorn JA. Inhibition of the oxidative metabolism of 3,4-dihydroxyphenylacetaldehyde, a reactive intermediate of dopamine metabolism, by 4-hydroxy-2-nonenal. Neurotoxicology. Jan;28(1):76-82, 2007. PMID: 16956664